Next-generation digital polymerase chain reaction assay for BCR::ABL1 in chronic myeloid leukemia: comprehensive validation for standardized measurable residual disease detection
Yong-Hwi Kim, Min-Sik Jang, Shin-Hyun Kim, In-Young Roh, Bong-Suk Kim, Kyung-Mi Kee, Soo-Hyun Kim, Dong-Wook Kim, Jae-Hoon Kim · 2026
Read Next-generation digital polymerase chain reaction assay for BCR::ABL1 in chronic myeloid leukemia: comprehensive validation for standardized measurable residual disease detection by Yong-Hwi Kim, Min-Sik Jang, Shin-Hyun Kim, In-Young Roh, Bong-Suk Kim, Kyung-Mi Kee, Soo-Hyun Kim, Dong-Wook Kim, Jae-Hoon Kim (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13675441.txt.
Description
Yong-Hwi Kim and co-authors present, in a 2026 validation study, a new digital test for leftover disease in chronic myeloid leukemia. The standard test can miss tiny amounts of the cancer signal in patients who respond deeply to treatment. A more sensitive count could catch relapse risk earlier.
The new kit counts copies of the fused gene that drives this leukemia, one molecule at a time. The team checked it against formal validation rules using known positive and negative samples. They also used the world standard sample to set the scale. A cutoff of at least two positive droplets marked a sample as positive. Careful checks like these decide whether a sharper test can be trusted in daily lab work.
Catalog record
| CREATOR | Yong-Hwi Kim, Min-Sik Jang, Shin-Hyun Kim, In-Young Roh, Bong-Suk Kim, Kyung-Mi Kee, Soo-Hyun Kim, Dong-Wook Kim, Jae-Hoon Kim |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 62 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |